Does diabetes affect colorectal cancer outcomes?

Top line:

Some patients have colorectal cancer (CRC) found that while patients with diabetes with complications had an increased risk of poor survival compared to their peers without diabetes, patients with diabetes without complications did not have significantly worse cancer outcomes.

methodology:

• This population-based retrospective cohort study used data from 2007 to 2015 from the Taiwan Cancer Registry linked to National Insurance and Death Registry data.

• The analysis included 59,202 adults with stage I-III colorectal cancer who underwent potentially curative surgery: 44,944 without diabetes, 8,864 with simple diabetes, There were 5,394 people with complex diabetes.

• The association between diabetes severity and colorectal cancer survival, overall survival (OS), disease-free survival (DFS), time to recurrence, and cancer-specific survival (CSS) was investigated.

remove:

• Patients with diabetes without complications had a slightly worse OS (hazard ratio) [HR]1.05), DFS (HR, 1.08), and CSS (HR, 0.98) compared to colleagues without diabetes.

• Patients with diabetes with complications had a significantly higher risk of poor OS (HR, 1.85), DFS (HR, 1.75), and CSS (HR, 1.41) compared to patients without diabetes.

• People with diabetes have a higher risk of colorectal cancer recurrence than people without diabetes.

• Excluding recurrence risk, the impact of comorbid diabetes on colorectal cancer survival, or OS, DFS, and CSS, was more pronounced among women and patients with early-stage cancer.

in fact:

“These findings show that preventing complications of diabetes may help improve survival for patients with colorectal cancer, especially women and those in the early stages of the disease. Therefore, a multidisciplinary approach is recommended for patients with colorectal cancer,” the authors conclude.

sauce:

The study was led by lead author Shin Ying Su, M.D., Ph.D., of National Taiwan University in Taipei. Published online Diary of October 23rd cancer.

Limitations:

Only patients from Taiwan were included, limiting generalizability as the prognosis of CRC may vary depending on ethnicity and cancer treatment strategy, factors that may vary between countries. Data on blood glucose levels and duration of diabetes were not available, which could have led to misclassification of diabetic status.

Disclosure:

Funding was provided by the Ministry of Science and Technology and the Ministry of Health. The authors have disclosed no relevant financial relationships.

For more news, follow Medscape Facebook, X, InstagramYouTube.